US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Valneva SE

2.82

+0.0000

Volume:- -

Turnover:- -

Market Cap:457.27M

PE:-14.88

High:2.82

Open:2.82

Low:2.82

Close:2.82

Loading ...

Overview Company News Filings

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Exploring Three High Growth Tech Stocks In Europe

Simply Wall St.

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...

High Growth Tech Stocks In Europe For March 2025

Simply Wall St.

VALNEVA Declaration of shares and voting rights: February 28, 2025

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Shareholding declaration Valneva SE - January 2025

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA - Declaration of shares and voting rights: November 30, 2024

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INRLF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"INRLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INRLF\",,,,,undefined,":{"symbol":"INRLF","market":"US","secType":"STK","nameCN":"Valneva SE","latestPrice":2.82,"timestamp":1746040800000,"preClose":2.82,"halted":0,"volume":0,"delay":15,"floatShares":121308760,"shares":162152579,"eps":-0.189561,"marketStatus":"Trading","change":0,"latestTime":"04-30 15:20:00 EDT Delay","open":2.82,"high":2.82,"low":2.82,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.189561,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":2.82,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INRLF\",,,,,undefined,":{"symbol":"INRLF","floatShares":121308760,"roa":"-10.03%","roe":"-7.91%","lyrEps":-0.808756,"shares":162152579,"dividePrice":0,"high":2.82,"amplitude":0,"preClose":2.82,"low":2.82,"week52Low":1.88,"pbRate":"2.22","psRate":"2.38","week52High":4.62,"institutionHeld":0,"latestPrice":2.82,"eps":-0.189561,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.189561,"open":2.82,"prevYearClose":2.09,"prevWeekClose":2.82,"prevMonthClose":3.5,"prevQuarterClose":3.5,"fiveDayClose":2.82,"twentyDayClose":3.5,"sixtyDayClose":2.4812},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INRLF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528322647","title":"Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2528322647","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528322647?lang=en_us&edition=fundamental","pubTime":"2025-04-16 23:45","pubTimestamp":1744818300,"startTime":"0","endTime":"0","summary":"Saint-Herblain , April 16, 2025 – Valneva SE , a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Companys Chief Executive Officer, Thomas Lingelbach, a team of Valnevas senior managers will participate in multiple events, including an important presentation on the Companys vaccine IXCHIQ, the world’s first licensed chikungunya vaccine.The Company will have a display in the exhibit area of the congress at booth #424.In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the most advanced Lyme disease vaccine candidate worldwide, currently in Phase 3, partnered with Pfizer.About IXCHIQ IXCHIQ is the world’s first licensed chikungunya vaccine available to address this sig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-participate-multiple-events-25th-154500336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","VALN","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","IE00B19Z3B42.SGD","LU0122379950.USD","SG9999001176.USD","SG9999002224.SGD","INRLF","LU1057294990.SGD","BK4139","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":1},{"id":"2526807498","title":"Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2","url":"https://stock-news.laohu8.com/highlight/detail?id=2526807498","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526807498?lang=en_us&edition=fundamental","pubTime":"2025-04-09 13:00","pubTimestamp":1744174800,"startTime":"0","endTime":"0","summary":"Saint Herblain  and Schlieren , April 9, 2025 – Valneva SE , a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 , the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis.Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella of which 62.3 million occur in children younger than five years1. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world.In November 2024, Valneva and LimmaTech announced vaccination of the first participant in a Phase 2b controlled human infection model  study of S4V2 , in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-limmatech-announce-first-vaccination-050000517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHIM","VALN","INRLF","BK4139"],"gpt_icon":0},{"id":"2525835055","title":"Exploring Three High Growth Tech Stocks In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2525835055","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525835055?lang=en_us&edition=fundamental","pubTime":"2025-04-08 13:08","pubTimestamp":1744088881,"startTime":"0","endTime":"0","summary":"The European market has recently experienced significant declines, with the pan-European STOXX Europe 600 Index dropping 8.44% amid heightened trade tensions and economic uncertainty stemming from new U.S. tariffs. In this challenging environment, identifying high growth tech stocks in Europe requires a focus on companies that demonstrate resilience through innovation and adaptability to evolving market conditions.Click here to see the full list of 238 stocks from our European High Growth Tech and AI Stocks screener.Overview: Pharming Group N.V. is a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and internationally, with a market cap of 484.22 million.Operations: Pharming Group specializes in developing and commercializing therapies for rare diseases, focusing on protein replacement and precision medicines. The company operates across the United States, Europe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-050801697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VALN","INRLF","BK4139","PHAR","PHGUF"],"gpt_icon":0},{"id":"2522033880","title":"Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522033880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522033880?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:00","pubTimestamp":1743008400,"startTime":"0","endTime":"0","summary":"Saint-Herblain , March 26, 2025 – Valneva SE  , a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on Form F-3, filed on March 25, 2025 with the U.S. Securities and Exchange Commission  relating to its existing At-the-Market offering facility , which was originally entered into in August 2022 and has not been utilized to-date.For any ADSs requested to be sold by the Company to eligible investors, Jefferies, as sales agent, will use commercially reasonable efforts to arrange the sale on the Company’s behalf, consistent with Jefferies’ normal sales and tra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-renews-sales-agreement-connection-170000319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VALN","INRLF"],"gpt_icon":0},{"id":"2521765797","title":"Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion","url":"https://stock-news.laohu8.com/highlight/detail?id=2521765797","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521765797?lang=en_us&edition=fundamental","pubTime":"2025-03-24 14:00","pubTimestamp":1742796000,"startTime":"0","endTime":"0","summary":"Saint Herblain , March 24, 2025 – Valneva SE , a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé , to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ remains available for purchase in France .Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness 8, with support from the EU Horizon Europe p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-responds-french-government-call-060000542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","INRLF","BK4190","CEPI","BK4566","BK4135","HAS","SII","CDC","VALN","BK4139","BK4588"],"gpt_icon":0},{"id":"2521421557","title":"Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2521421557","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521421557?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:04","pubTimestamp":1742540652,"startTime":"0","endTime":"0","summary":"Total Product Sales: EUR163.3 million, a 13% increase over 2023.IXIARO Sales: EUR94.1 million, a 28% growth compared to 2023.DUKORAL Sales: EUR32.3 million, an 8% increase from the previous year.IXCHIQ Initial Sales: EUR3.7 million following its launch in 2024.Operating Profit: EUR20.7 million, driven by non-recurring income from the sale of a priority review voucher.Cash Position: EUR168 million in cash and cash equivalents at year-end 2024.R&D Expenses: EUR74.1 million, a 24% increase from 2023.Gross Margin of Commercial Products: 50.6%, up from 46% in 2023.2025 Revenue Guidance: Total product sales expected to reach EUR170-180 million.Valneva SE  reported a decrease in third-party sales due to supply constraints and a strategic focus on proprietary products.Valneva SE  acknowledged that the ramp-up of IXCHIQ sales was slower than anticipated, requiring a revision of midterm sales guidance.Q: Can you elaborate on the cash burn guidance, which is going down by over 50%, and provide co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-se-inrlf-fy-2024-070412143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INRLF","VALN"],"gpt_icon":0},{"id":"2518261673","title":"High Growth Tech Stocks In Europe For March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518261673","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518261673?lang=en_us&edition=fundamental","pubTime":"2025-03-10 13:08","pubTimestamp":1741583284,"startTime":"0","endTime":"0","summary":"As European markets navigate the complexities of U.S. trade policy uncertainty and fluctuating economic indicators, the STOXX Europe 600 Index recently snapped a 10-week streak of gains, reflecting broader investor caution despite positive developments in Germany's defense and infrastructure spending. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience and adaptability to shifting market dynamics while capitalizing on technological advancements and strategic opportunities within the sector.Click here to see the full list of 245 stocks from our European High Growth Tech and AI Stocks screener.ENXTPA:EXN Revenue and Expenses Breakdown as at Mar 2025. Overview: Valneva SE is a specialty vaccine company that focuses on developing, manufacturing, and commercializing vaccines for infectious diseases with unmet needs, and it has a mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-europe-050804459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VALN","EXNWF","INRLF","BK4139"],"gpt_icon":0},{"id":"2517944779","title":"VALNEVA  Declaration of shares and voting rights: February 28, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944779","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517944779?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:00","pubTimestamp":1741194000,"startTime":"0","endTime":"0","summary":"Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain Regulated market of Euronext Paris - Compartment B. Number of shares composing the share capital of Valneva. Total number of voting rights including suspended voting rights*. Total number of voting rights excluding suspended voting rights**. 162,521,524ordinary shares with a par value of 0.15 each. Double voting rights granted on 907 ordinary sharesTransfer into bearer form of 142 shares with double voting rights. Between February 7 & February 21, 2025Between February 6 & February 14, 2025. * Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.** Net  voting rights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-declaration-shares-voting-rights-170000351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INRLF","VALN"],"gpt_icon":0},{"id":"2516209572","title":"Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2516209572","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516209572?lang=en_us&edition=fundamental","pubTime":"2025-03-03 14:00","pubTimestamp":1740981600,"startTime":"0","endTime":"0","summary":"Management will discuss Valneva’s pipeline of potential first-in-class vaccine candidates, including its lead Lyme disease vaccine, VLA15, and its Shigella and Zika programs alongside the Company’s portfolio of marketed vaccines, which are expected to generate 170-180 million in revenue in 2025.The TD Cowen presentation will be webcast live and available as a replay in the “investor” section of the Valneva website at www.valneva.com.Attending institutional investors who would like to meet with Valneva management are asked to submit a request to their representative at the respective bank.About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.We have a strong track record, havi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-present-upcoming-td-cowen-060000963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INRLF","TD","BK4566","BK4127","BK4137","VALN","COWN","BK4207","HCSG","BK4585","BK4139"],"gpt_icon":0},{"id":"2516712473","title":"Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2516712473","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516712473?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:45","pubTimestamp":1740761100,"startTime":"0","endTime":"0","summary":"If granted, IXCHIQ will become the first vaccine against the chikungunya virus  available in the EU for adolescents 12 years of age and older. Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative to ensure the vaccine is available to all age groups. Therefore, this positive CHMP opinion marks a crucial milestone toward introducing a more robust preventative solution against chikungunya in the EU. Broader accessibility will help provide protection and mitigate the burden of this debilitating illness, which is continuing to spread in areas that were previously unaffected.”The CHMP positive opinion follows four regulatory approvals in the U.S6., Europe7, Canada8 and the UK9 in adults 18 years of age and older. Valneva expects to receive marketing approval in Brazil in the first quarter of 2025, which would represent the first approval in an ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-receives-ema-positive-chmp-164500042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INRLF","BK4539","BK4201","CEPI","VALN","SII","BK4156","EC","BK4087","BK4139","BK4135","CHMP"],"gpt_icon":0},{"id":"2512189659","title":"Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2512189659","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512189659?lang=en_us&edition=fundamental","pubTime":"2025-02-18 14:00","pubTimestamp":1739858400,"startTime":"0","endTime":"0","summary":"Met 2024 growth targets for sales revenue  and total revenues . Substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025. 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn. Saint-Herblain , February 18, 2025 – Valneva SE  a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. The Company will publish its 2024 audited consolidated financial statements and host an analyst call on March 20, 2025.Total revenues were 169.6 million for the year ended December 31, 2024 compared to 153.7 million in the year ended December 31, 2023, an increase of 10%. Product sales revenue reached 163.3 million for the year ended December 31, 2024 compared to 144.6 million in the same period of 2023, an increase of 13%. Secured three additiona","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-reports-preliminary-unaudited-2024-060000747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VALN","INRLF"],"gpt_icon":0},{"id":"2509209231","title":"Shareholding declaration Valneva SE - January 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209231","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209231?lang=en_us&edition=fundamental","pubTime":"2025-02-07 01:00","pubTimestamp":1738861200,"startTime":"0","endTime":"0","summary":"Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain Regulated market of Euronext Paris - Compartment B. Number of shares composing the share capital of Valneva. Total number of voting rights including suspended voting rights*. Total number of voting rights excluding suspended voting rights**. 162,521,524  ordinary shares with a par value of 0.15 each. Double voting rights granted on 2282 ordinary shares. * Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.** Net  voting rights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shareholding-declaration-valneva-se-january-170000380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VALN","INRLF","BK4139"],"gpt_icon":0},{"id":"2507675398","title":"Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2507675398","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507675398?lang=en_us&edition=fundamental","pubTime":"2025-01-31 00:45","pubTimestamp":1738255500,"startTime":"0","endTime":"0","summary":"Saint Herblain , January 30, 2025 – Valneva SE , a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States  Department of Defense  for the supply of its Japanese encephalitis  vaccine, IXIARO.Under this new one-year contract, the DoD will buy a minimum of $32.8 million worth of IXIARO vaccines and has the possibility to purchase additional doses during the coming twelve months.Deliveries of IXIARO doses have continued in 2024 under the supply contract signed in September 20231. The new contract will commence immediately.Dipal Patel, Chief Commercial Officer of Valneva commented, “We are honored to continue our long-term relationship with the DoD. The U.S. military has trusted IXIARO for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”IXIARO is the only JE vaccine approved by the U.S. Food and Drug Administration","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-announces-ixiaro-supply-contract-164500837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VALN","INRLF"],"gpt_icon":0},{"id":"2505278755","title":"Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278755","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278755?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:05","pubTimestamp":1737461100,"startTime":"0","endTime":"0","summary":"Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents  for its single-shot chikungunya virus  vaccine, IXCHIQ. For investors’ note, IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need.The trial data supports and strengthens the pivotal data previously reported for adolescents in the United States, Europe and Canada. Data from this trial are also expected to support the licensure of IXCHIQ in Brazil.The new favorable data from the Phase 3 trial helped Valneva advance the furthest along the clinical development timeline.Subsequent to the news, the share price of VALN jumped 1.4% to $4.37 yesterday.The latest development is capable of generating positive market sentiment, considering the rising number of chikungunya cases in select geographies. We therefore expect market sentiment toward VALN stock to be positive surrounding this news.Additionally, the compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/favorable-vla1553-321-phase-3-120500966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4567","CEPI","OMCL","BK4139","BK4504","INRLF","BK4548","BK7007","RMD.AU","BK4156","LU2008162690.USD","BK4588","BK4082","BK4539","BK4585","LU2177674079.SGD","VCYT","RMD","BK7501","VALN","BK4167"],"gpt_icon":0},{"id":"2505238242","title":"Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2505238242","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505238242?lang=en_us&edition=fundamental","pubTime":"2025-01-21 00:45","pubTimestamp":1737391500,"startTime":"0","endTime":"0","summary":"Geometric mean antibody titers  consistently surpassed the seroresponse threshold defined with the U.S. Food and Drug Administration 7 as the surrogate of protection in baseline seronegative participants who received a single dose of the vaccine.Conducted in collaboration with Instituto Butantan in Brazil and funded by the Coalition for Epidemic Preparedness Innovations  with support from the European Union ’s Horizon 2020 program, the VLA1553-321 trial represents the first clinical trial conducted in an endemic area and with individuals previously infected with CHIKV. This trial supported the submission of label extension applications to the U.S. Food and Drug Administration 8, the European Medicines Agency  and Health Canada9 to po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-reports-high-sustained-immune-164500324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INRLF","CEPI","VALN","SII","BK4156","BK4139","BK4135"],"gpt_icon":0},{"id":"2501252128","title":"Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2501252128","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501252128?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:45","pubTimestamp":1736181900,"startTime":"0","endTime":"0","summary":"Saint Herblain , January 6, 2025 – Valneva SE , a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco.Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which is expected to generate 160 - 170 million in revenues in 2024, and highlight upcoming catalysts from its clinical development pipeline, including the pivotal data readout for its Lyme disease vaccine later this year.To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at investors@valneva.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-meet-investors-during-j-164500780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2271345857.HKD","BK4137","LU0912757837.SGD","LU0158827948.USD","VALN","BK4127","BK4585","LU1363072403.SGD","LU2357305700.SGD","LU1732800096.USD","LU0971096721.USD","LU2089283258.USD","LU0006306889.USD","BK4516","INRLF","LU0267386448.USD","LU1720051108.HKD","BK4504","LU0314104364.USD","LU2023251221.USD","LU2089284900.SGD","LU0106261372.USD","HCSG","IE00BKVL7J92.USD","LU0795875086.SGD","LU1162221912.USD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1548497426.USD","LU0158827781.USD","LU2347655156.SGD","LU0106831901.USD","BK4588","LU1074936037.SGD","BK4581","LU0320765646.SGD","LU1989772840.SGD","BK4139","LU1989772923.USD","ISBC","BK4534","LU0225283273.USD","LU2028103732.USD","BK4211","LU1668664300.SGD","LU0098860793.USD","LU2111349929.HKD","BK4539","LU0795875169.SGD"],"gpt_icon":0},{"id":"2500149174","title":"VALNEVA  Declaration of shares and voting rights: December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500149174","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500149174?lang=en_us&edition=fundamental","pubTime":"2025-01-04 01:00","pubTimestamp":1735923600,"startTime":"0","endTime":"0","summary":"Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain Regulated market of Euronext Paris - Compartment B. Number of shares composing the share capital of Valneva. Total number of voting rights including suspended voting rights*. Total number of voting rights excluding suspended voting rights**. 162,521,524 ordinary shares with a par value of 0.15 each. Transfer into bearer form of 300 shares with double voting rightsSale of 150 shares with double voting rightsDefinitive attribution of 27,521 free ordinary shares Double voting rights granted on 6,177 ordinary shares. December 2, 2024December 5, 2024December 6, 2024Between December 1& 28, 2024. * Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.** Net","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-declaration-shares-voting-rights-170000544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INRLF","VALN"],"gpt_icon":0},{"id":"2489483766","title":"VALNEVA - Declaration of shares and voting rights: November 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489483766","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489483766?lang=en_us&edition=fundamental","pubTime":"2024-12-05 14:30","pubTimestamp":1733380200,"startTime":"0","endTime":"0","summary":"Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain Regulated market of Euronext Paris - Compartment B. Number of shares composing the share capital of Valneva. Total number of voting rights including suspended voting rights*. Total number of voting rights excluding suspended voting rights**. 162,494,003 ordinary shares with a par value of 0.15 each. Transfer into bearer form of 1,000 shares with double voting rights  Double voting rights granted on 7,052 ordinary shares. * Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.** Net  voting rights.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-declaration-shares-voting-rights-063000798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INRLF","BK4539","VALN","BK4139"],"gpt_icon":0},{"id":"2488139377","title":"Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2488139377","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488139377?lang=en_us&edition=fundamental","pubTime":"2024-12-04 14:00","pubTimestamp":1733292000,"startTime":"0","endTime":"0","summary":"Saint-Herblain , December 4, 2024 – Valneva SE , a specialty vaccine company, today announces the publication of an article on the global health and economic burden of mosquito-borne disease chikungunya in The British Medical Journal , one of the world’s leading peer-reviewed medical journals.The article, titled, “The Global Health and Economic Burden of Chikungunya from 2011 to 2020: A Model-Driven Analysis on the Impact of an Emerging Vector-Borne Disease,” shows that chikungunya has a higher disease burden than was previously estimated, and costs related to the disease are substantial. According to the BMJ article, chikungunya could significantly impact local health systems due to its unpredictable and explosive nature.About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-announces-peer-reviewed-publication-060000854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INRLF","VALN"],"gpt_icon":0},{"id":"2488957243","title":"Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957243","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957243?lang=en_us&edition=fundamental","pubTime":"2024-12-03 14:00","pubTimestamp":1733205600,"startTime":"0","endTime":"0","summary":"Antibody levels remained high at 96% seroresponse in line with the two-year persistence data. This long-lasting antibody persistence was comparable in older (65+) and younger adults. Saint-Herblain , December 3, 2024 – Valneva SE , a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The three-year persistence data are also in line with positive twelve-month and two-year persistence data the Company reported in December 20221 and 20232, respectively.IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is currently approved in the U.S.4, Europe5, and Canada6 for the prevention of disease caused by the chikungunya virus in individuals 18","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dcoj_y6ZGAO7ZsNVSQf7nA--~B/aD0xNDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b71e6b080fbb9f52051d91fc548d0900"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-reports-positive-three-antibody-060000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VALN","BK4179","INRLF","BK4156","CDC","AESI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INRLF\",params:#limit:5,,,undefined,":[{"date":"2024-05-07","symbol":"INRLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715068800000,"name":null,"time":"","dateTimestamp":1715054400000,"actualEps":null},{"market":"US","date":"2024-03-20","symbol":"INRLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710907200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-09-21","symbol":"INRLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1695268800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-11-10","symbol":"INRLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668056400000,"reportTimeType":"pre","actualEps":null},{"date":"2022-03-24","symbol":"INRLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1648108800000,"name":null,"time":"","dateTimestamp":1648094400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INRLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INRLF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.5,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1687320000000}}}